August 2, 2016 —The U.S. Food and Drug Administration (FDA) granted market clearance for W. L. Gore & Associates’ Gore ...
Stents Drug Eluting
This channel includes news and new technology innovations for drug eluting stents (DES). These drug coated stents were developed to solve a frequent problem with bare metal stents, which can cause neointimal hyperplasia (scar tissue growth) in some patients. The antiproliferative drugs used on DES prevent the growth of tissue. One downside of DES is the requirement for patients to take long-term antiplatelet therapy to prevent the possible formation of clots on these stents. Newer generation DES use technologies help the vessels heal faster, which may allow reduce the duration of dual antiplatelet therapy (DAPT), or use a single drug, usually eliminating aspirin. This section includes news for both metallic and bioresorbable drug-eluting stents and related clinical trial data.
June 3, 2016 — Biotronik announced results establishing non-inferiority of the Orsiro hybrid drug-eluting stent (DES) to ...
![](/sites/default/files/styles/content_feed_large/public/field/image/X0000_Biosensors_Biomatrix%20stent.png?itok=mpnQo0wD)
May 16, 2016 — Cardinal Health announced it has entered into a distribution agreement with Biosensors that enables ...
April 21, 2016 — Medtronic plc announced new clinical data from one of the endpoints in the RevElution Trial for its ...
![Absorb, bioresorbable stents](/sites/default/files/styles/content_feed_large/public/field/image/X0000_Abbott_Absorb%20stent%20held%20by%20fingers.jpeg?itok=CaOCpQMA)
Bioresorbable stents have been one of the hottest new cardiovascular technologies discussed at cardiology meetings over ...
March 7, 2016 — Biotronik announced publication of results from the BIOSCIENCE trial in the journal EuroIntervention ...
February 2, 2016 — Medtronic plc announced the recent CE Mark and commercial launch for an expanded size matrix of the ...
January 8, 2016 — In December, Stentys announced completion of patient enrollment in DESSOLVE III. The 1,400-patient ...
For the past few years, the focus of the annual Transcatheter Cardiovascular Therapeutics (TCT) meetings has been on ...
DAIC Editor Dave Fornell offers his choices for the most innovative new interventional cardiovascular technologies ...
Tom Watson, clinical analyst for MDBuyLine, and DAIC Editor Dave Fornell discuss some of the new cardiovascular and ...
October 30, 2015 — Results from a clinical trial showed that that the Abbott Absorb everolimus-eluting bioresorbable ...
Dr. Stephen Worthley, Ph.D., director of the cardiac cath labs at Royal Adelaide Hospital at the University of Adelaide ...
Dean Kereiakes, M.D., medical director of The Christ Hospital Heart and Vascular Center, and a lead investigator for ...
October 27, 2015 — Results from the multicenter, prospective, randomized PANDA III trial indicate that the BuMA sirolimu ...